President Donald Trump’s proposal to peg US drug prices to those paid abroad includes granting the FDA legal authority to revoke drug approvals if manufacturers don’t meet pricing targets under the plan, a provision that is likely to face fierce legal resistance from industry if applied. Trump’s executive order signed earlier this month revives his “most favored nation” policy that seeks to slash US drug costs by directing manufacturers to match prices to the lowest ones paid in other countries. “It really paints a potential picture for drug manufacturers that FDA could take a quite a wide view of what safety and efficacy is,” said Julie Tibbets, chair of Goodwin’s life science regulatory and compliance practice. “One thing companies should be starting to think about is if the scrutiny were to lead to a reopening of their safety and efficacy records on which their original approvals were based, where the weaknesses may be in the data that’s emerged.” Read the Bloomberg Law article for more.